NCT06888921 - A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 21, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Ovarian CancerOvarian Cancer Recurrent

Interventions

DRUG

COM701

COM701 will be administered via intravenous (IV) infusion once every 3 weeks.

DRUG

Normal Saline

Saline will be administered via intravenous (IV) infusion once every 3 weeks

Trial Locations (11)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center- Main Campus, New York

13009

RECRUITING

Institut Paoli-Calmettes, Marseille

35042

RECRUITING

Centre Eugene Marquis, Rennes

38138

RECRUITING

West Cancer Center, Germantown

43026

RECRUITING

Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Hilliard

49503

RECRUITING

Corewell Health, Grand Island

60637

RECRUITING

The University of Chicago Medical Center, Chicago

3109601

RECRUITING

Rambam Health Care Campus, Haifa

7747629

RECRUITING

Assuta Medical Center, Ashdod

9103102

RECRUITING

Shaare Zedek Medical Center, Jerusalem

9112001

RECRUITING

Hadassah, University Hospital Ein Kerem, Jerusalem